BOCA RATON, Fla., July 9, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that Nestle Health Science-Pamlab and Merck & Cie have dismissed their patent litigation against Macoven Pharmaceuticals, LLC., and Breckenridge has dismissed its Lanham Act litigation against Macoven. In return, Macoven has agreed to immediately and permanently cease all manufacturing, use, sale, offers for sale, importation, distribution, advertising, promotion, marketing its generic, unlicensed L-methylfolate calcium salt products. Macoven's discontinued products include: VitaCirc-B, Alz-NAC, L Methylfolate PNV DHA, L-Methylfolate Calcium 7.5, and L-Methylfolate Calcium 15.
Merck & Cie is the exclusive manufacturer and supplier of the ingredient Metafolin® (L-methylfolate calcium), and is the owner of multiple U.S. patents covering Metafolin®. Nestle Health Science-Pamlab markets the only branded medical foods in the United States which contain Metafolin®. Since 2007, Breckenridge has served as the exclusive authorized-generic supplier of Nestlé Health Science-Pamlab brands, from folic acid products to Metafolin®-containing medical foods.
About Breckenridge Pharmaceutical, Inc.
Breckenridge is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, and Powders.
|SOURCE Breckenridge Pharmaceutical, Inc.|
Copyright©2012 PR Newswire.
All rights reserved